Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Nadav Sarid, Tsofia Levi, Ofir Wolach, Yair Herishanu

Blood (2024) 144 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2024-205236

Published: 2024

Journal Articles

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Albert Kolomansky, MD, Irit Kay, MD, Nathalie Ben-Califa, PhD, Anton Gorodov, BSc, Zamzam Awida, BSc, Ofer Sadovnic, MD, Maria Ibrahim, BSc, Tamar Liron, PhD, Sahar Hiram-Bab, PhD, Howard S. Oster, MD PhD, Nadav Sarid, MD, Chava Perry, MD PhD, Yankel Gabet, DMD, PhD, Moshe Mittelman, MD, Drorit Neumann, PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142295

Published: 2020

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer

Blood (2017) 130 (Supplement 1): 1563.

https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563

Published: 2017

Journal Articles

Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Dana Rosenberg, MD, Erel Joffe, MDMSc, Uri Rozovski, MD, Chava Perry, MDPhD, Ilya Kirgner, MD, Svetlana Trestman, MD, Odelia Gur, Freddy Aviv, MD, Nadav Sarid, MD, Albert Kolomansky, MD, Lily Gepstein, Yair Herishanu, MD, Elizabeth Naparstek, MD

Blood (2015) 126 (23): 3188.

https://doi.org/10.1182/blood.V126.23.3188.3188

Published: 2015

Journal Articles

Dividing plasma cells in the cerebrospinal fluid of a patient with refractory multiple myeloma

Nadav Sarid, Ben-Zion Katz

Blood (2015) 126 (18): 2162.

https://doi.org/10.1182/blood-2015-07-661751

Published: 2015

NARROW

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Dividing plasma cells in the cerebrospinal fluid of a patient with refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Dividing plasma cells in the cerebrospinal fluid of a patient with refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only